[Anticoagulation in atrial fibrillation and antiplatelet in diabetes mellitus type 2. How do we do it?].
In spite of evidence about the interest of anticoagulation in Atrial Fibrillation (AF) and antiplatelet to diabetics (DM) type 2, the national and international references describe a low level of assumption of those criteria in practice. Published studies on these aspects are unavailable in Navarre. Cross-sectional study. primary care patients (1,600 people > 15 years). patients diagnosed of AF / with diagnosis of DM type 2, over 40. age and sex, criteria of AF with high embolic risk (>6% annual) and cardiovascular risk factors in DM2. in computerised registers of Organisation and Management Information. (population universe studied), results in absolute numbers and percentages. Twenty-five people with diagnosis of chronic FA (14 women and 11 men, average age 78.36 years); 22 (81.8%) show high embolic risk. There were counter-indications in 4 cases. Type 2 diabetics totalled 69 people (29 women and 40 men, average age 68.57 years). There are 16 (23.1%) in primary prevention (PP), 26 (37.3%) in secondary prevention (SP), and 27 (39.1%) do not follow antiplatelet therapy. There is counter-indication in 8 cases and 14 patients (20.2%) would be susceptible to intervention. The results of oral anticoagulant therapy (OAT) in high risk AF exceed the reviewed references. The PP with DM2 are similar figures to other studies; a area of improvement was detected. We must ask for the opinion of the patient and individualise these therapies. The family doctor has a significant responsibility in cardiovascular prevention of the patients affected by these problems.